Only 38% of Americans say that they are either very confident or somewhat confident that the administration’s plan will result in paying less for their prescription drugs.
When the Trump administration unveiled the “American Patients First” blueprint to lower drug prices in May 2018, it indicated that its priorities were improving competition, improving negotiation, lowering list prices for drugs, and reducing out-of-pocket spending for patients. At the time, stakeholders met the plan with cautious optimism.
However, according to a recent poll conducted by the Kaiser Family Foundation, only 38% of Americans say that they are either very confident or somewhat confident that the administration’s plan will result in paying less for their prescription drugs.
Click to read more about the drug pricing blueprint.
Republicans had the greatest level of confidence in the drug pricing plan, with 40% reporting that they were very confident and 43% reporting that they were somewhat confident that they would see lower prices for their medicines. By contrast, just 4% of Democrats were very confident, and 25% were somewhat confident, that they would experience a reduction in the prices that they pay for their drugs.
Furthermore, a majority of Americans (55%) said that the President’s strategy of publicly criticizing drug companies and calling for them to reduce the cost of their drugs was likely to be not at all effective or not too effective.
Increases in the amount that individuals pay for their healthcare are front-of-mind for a majority of Americans; 58% of respondents said they were “very concerned,” and 30% said they were “somewhat concerned,” about growing costs to individuals.
Americans overwhelmingly agree that pharmaceutical companies’ profits are a major reason behind continually rising healthcare costs; 78% of respondents cited drug company profits as a major reason for growing healthcare costs. Respondents also cited fraud and waste in the healthcare system (71%), overcharging by hospitals (71%), and excessive profits for insurance companies (70%) as the other major reasons for cost growth.
Kaiser’s poll also revealed that healthcare costs are a key issue for voters as the nation approaches the 2018 elections; when voters who said that they want candidates to talk about healthcare are asked which issue they most want to hear discussed, 27% of all voters mention the cost of healthcare. Cost was mentioned 3 times more frequently than any other healthcare issue, including universal coverage, increasing access, or Medicare concerns.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.